SUPPLEMENTAL MATERIAL

Permanent pacemaker implantation after On-X aortic valve replacement: SWEDEHEART observational cohort study

Magnus Dalén, MD, PhD,^{1,2} Michael Persson, MD,^{1,2} Natalie Glaser, MD, PhD,^{2,3}

Ulrik Sartipy, MD, PhD^{1,2}

 ${}^{1} Department \ of \ Cardiothoracic \ Surgery, \ Karolinska \ University \ Hospital, Stockholm, Sweden$

 ${}^2 Department\ of\ Molecular\ Medicine\ and\ Surgery,\ Karolinska\ Institutet,\ Stockholm,\ Sweden$

³Department of Cardiology, Stockholm South General Hospital, Stockholm, Sweden

Contents

upplemental Table 1. Number of patients by year of surgery	:
upplemental Table 2. Number of patients according to hospital	4
upplemental Table 3. Number of pacemaker implants by year of surgery	5
upplemental Table 4. Number of pacemaker implants according to hospital	6
upplemental Table 5. Baseline characteristics after IPTW.	7
upplemental Table 6. Baseline characteristics after overlap weighting	10
upplemental Table 7. Height, weight and body surface area	13
upplemental Figure 1. Proportion of On-X valves by year of surgery	14
upplemental Figure 2. Proportion of On-X valves according to hospital	15
upplemental Figure 3. Histogram of propensity scores before and after matching	16
upplemental Figure 4. Absolute standardized differences before (hollow circles) and after (filled ircles) propensity score matching.	17
upplemental Figure 5. Proportion of permanent pacemaker implants by year of surgery	18
upplemental Figure 6. Proportion of permanent pacemaker implants according to hospital	19
upplemental Figure 7. Absolute standardized differences before (hollow circles) and after (filled ircles) inverse probability of treatment weighting	2(
upplemental Figure 8. Absolute standardized differences before (hollow circles) and after (filled ircles) overlap weighting.	21
upplemental Figure 9. Kaplan-Meier estimated pacemaker implantation rate in the inverse robability of treatment weighted population	22
upplemental Figure 10. Kaplan-Meier estimated pacemaker implantation rate in the overlap reighted population	23
upplemental Figure 11. Crude and adjusted pacemaker implantation rate after On-X valve aortic alve replacement according to alternative approaches for confounding adjustment	24

Supplemental Table 1. Number of patients by year of surgery.

		On-X	valve
Year of surgery	Total study population n = 2602	No n = 2021	Yes n = 581
2005	251 (100%)	244 (97%)	7 (2.8%)
2006	237 (100%)	230 (97%)	7 (3.0%)
2007	215 (100%)	187 (87%)	28 (13%)
2008	214 (100%)	176 (82%)	38 (18%)
2009	152 (100%)	110 (72%)	42 (28%)
2010	166 (100%)	120 (72%)	46 (28%)
2011	133 (100%)	100 (75%)	33 (25%)
2012	145 (100%)	110 (76%)	35 (24%)
2013	157 (100%)	120 (76%)	37 (24%)
2014	158 (100%)	112 (71%)	46 (29%)
2015	141 (100%)	100 (71%)	41 (29%)
2016	221 (100%)	148 (67%)	73 (33%)
2017	193 (100%)	121 (63%)	72 (37%)
2018	219 (100%)	143 (65%)	76 (35%)

Supplemental Table 2. Number of patients according to hospital.

		On-X	valve
Hospital	Total study population $n = 2602$	No n = 2021	Yes n = 581
1	467 (100%)	413 (88%)	54 (12%)
2	340 (100%)	227 (67%)	113 (33%)
3	329 (100%)	304 (92%)	25 (7.6%)
4	120 (100%)	120 (100%)	0 (0%)
5	398 (100%)	398 (100%)	0 (0%)
6	331 (100%)	243 (73%)	88 (27%)
7	221 (100%)	215 (97%)	6 (2.7%)
8	396 (100%)	101 (26%)	295 (74%)

Supplemental Table 3. Number of pacemaker implants by year of surgery.

		Pacemaker w	ithin 30 days
Year of surgery	Total study population $n = 2602$	No n = 2487	Yes n = 115
2005	251 (100%)	243 (97%)	8 (3.2%)
2006	237 (100%)	226 (95%)	11 (4.6%)
2007	215 (100%)	209 (97%)	6 (2.8%)
2008	214 (100%)	207 (97%)	7 (3.3%)
2009	152 (100%)	144 (95%)	8 (5.3%)
2010	166 (100%)	157 (95%)	9 (5.4%)
2011	133 (100%)	130 (98%)	3 (2.3%)
2012	145 (100%)	139 (96%)	6 (4.1%)
2013	157 (100%)	151 (96%)	6 (3.8%)
2014	158 (100%)	153 (97%)	5 (3.2%)
2015	141 (100%)	135 (96%)	6 (4.3%)
2016	221 (100%)	207 (94%)	14 (6.3%)
2017	193 (100%)	182 (94%)	11 (5.7%)
2018	219 (100%)	204 (93%)	15 (6.8%)

Supplemental Table 4. Number of pacemaker implants according to hospital.

		Pacemaker within 30 days		
Hospital	Total study population $n = 2602$	No n = 2487	Yes n = 115	
1	467 (100%)	442 (95%)	25 (5.4%)	
2	340 (100%)	316 (93%)	24 (7.1%)	
3	329 (100%)	311 (95%)	18 (5.5%)	
4	120 (100%)	115 (96%)	5 (4.2%)	
5	398 (100%)	389 (98%)	9 (2.3%)	
6	331 (100%)	319 (96%)	12 (3.6%)	
7	221 (100%)	213 (96%)	8 (3.6%)	
8	396 (100%)	382 (96%)	14 (3.5%)	

Supplemental Table 5. Baseline characteristics after IPTW.

Baseline characteristics in patients who underwent mechanical aortic valve replacement with an On-X valve or other mechanical valves in Sweden from 2005 to 2018 before and after inverse probability of treatment weighting.

	Unweighted			IPTW*		
	Control	On-X	SMD	Control	On-X	SMD
Number of patients	2021	581		2573.7	2204.4	
Age (years), mean (SD)	54.1 (9.0)	51.0 (10.7)	0.322	53.5 (9.4)	52.8 (9.6)	0.067
Female sex	525 (26.0)	106 (18.2)	0.187	631.4 (24.5)	517.8 (23.5)	0.024
Non-Nordic birth region	207 (10.2)	32 (5.5)	0.176	238.7 (9.3)	148.1 (6.7)	0.094
Educational level			0.151			0.039
<10 years	588 (29.3)	132 (22.8)		716.6 (28.0)	579.0 (26.4)	
10-12 years	945 (47.1)	303 (52.2)		1230.2 (48.1)	1091.8 (49.8)	
>12 years	474 (23.6)	145 (25.0)		611.6 (23.9)	520.9 (23.8)	
Disposable household income (quartiles)			0.119			0.024
Q1 (low)	520 (25.7)	131 (22.5)		642.7 (25.0)	557.5 (25.3)	
Q2	506 (25.0)	145 (25.0)		648.0 (25.2)	547.9 (24.9)	
Q3	512 (25.3)	138 (23.8)		645.7 (25.1)	535.6 (24.3)	
Q4 (high)	483 (23.9)	167 (28.7)		637.3 (24.8)	563.5 (25.6)	
Married	1065 (52.7)	261 (44.9)	0.156	1318.3 (51.2)	1058.1 (48.0)	0.065
Body mass index (tertiles)			0.012			0.042
T1 (low)	623 (33.5)	185 (33.0)		804.0 (33.6)	743.2 (35.5)	

T2	618 (33.2)	189 (33.7)		798.0 (33.3)	685.6 (32.8)	
T3 (high)	620 (33.3)	187 (33.3)		791.3 (33.1)	663.3 (31.7)	
Atrial fibrillation	183 (9.1)	50 (8.6)	0.016	227.8 (8.9)	210.8 (9.6)	0.025
Heart failure	310 (15.3)	72 (12.4)	0.085	379.4 (14.7)	309.3 (14.0)	0.020
Left ventricular ejection fraction (%)			0.079			0.035
>50	1518 (75.1)	435 (74.9)		1935.0 (75.2)	1679.7 (76.2)	
30-50	389 (19.2)	122 (21.0)		499.8 (19.4)	422.0 (19.1)	
<30	114 (5.6)	24 (4.1)		138.8 (5.4)	102.7 (4.7)	
Chronic obstructive pulmonary disease	136 (6.7)	19 (3.3)	0.159	155.5 (6.0)	96.5 (4.4)	0.075
Diabetes	301 (14.9)	60 (10.3)	0.138	360.6 (14.0)	254.6 (11.5)	0.074
eGFR (ml/min/1,73 m²)			0.154			0.050
>60	1865 (93.6)	554 (96.9)		2392.7 (94.3)	2066.5 (95.0)	
45-59	85 (4.3)	12 (2.1)		97.5 (3.8)	78.0 (3.6)	
30-44	24 (1.2)	4 (0.7)		27.1 (1.1)	22.7 (1.0)	
<30	18 (0.9)	2 (0.3)		20.3 (0.8)	9.2 (0.4)	
Preoperative dialysis	19 (1.0)	2 (0.4)	0.077	21.5 (0.9)	9.5 (0.5)	0.052
Prior myocardial infarction	193 (9.5)	42 (7.2)	0.084	235.7 (9.2)	173.2 (7.9)	0.047
Prior percutaneous coronary intervention	102 (5.0)	25 (4.3)	0.035	123.8 (4.8)	116.7 (5.3)	0.022
Peripheral vascular disease	208 (10.3)	97 (16.7)	0.188	297.4 (11.6)	294.6 (13.4)	0.055
Hypertension	703 (34.8)	217 (37.3)	0.053	905.7 (35.2)	789.8 (35.8)	0.013
Hyperlipidemia	344 (17.0)	89 (15.3)	0.046	431.7 (16.8)	317.2 (14.4)	0.066
Prior stroke	105 (5.2)	31 (5.3)	0.006	139.3 (5.4)	119.6 (5.4)	0.001
	103 (3.2)	31 (3.3)	0.000	133.3 (3.4)	113.0 (3.4)	0.001

History of cancer	98 (4.8)	30 (5.2)	0.014	126.0 (4.9)	116.2 (5.3)	0.017
Alcohol dependence	69 (3.4)	15 (2.6)	0.049	84.6 (3.3)	50.8 (2.3)	0.059
Liver disease	18 (0.9)	3 (0.5)	0.045	20.9 (0.8)	9.5 (0.4)	0.049
Prior bleeding event	67 (3.3)	15 (2.6)	0.043	81.4 (3.2)	72.6 (3.3)	0.008
Prior endocarditis	92 (4.6)	26 (4.5)	0.004	118.3 (4.6)	116.2 (5.3)	0.031
Emergent operation	32 (1.6)	11 (1.9)	0.024	41.5 (1.6)	36.9 (1.7)	0.005
Coronary artery bypass grafting	363 (18.0)	79 (13.6)	0.120	438.9 (17.1)	296.2 (13.4)	0.101
Valve size (mm)			0.254			0.075
19-21	450 (22.7)	149 (25.8)		589.5 (23.2)	548.5 (25.3)	
23	704 (35.4)	256 (44.3)		944.9 (37.3)	841.0 (38.8)	
25-27	832 (41.9)	173 (29.9)		1001.4 (39.5)	780.5 (36.0)	
						-

Numbers are n (%) unless otherwise specified.

eGFR = estimated glomerular filtration rate, SD = standard deviation, SMD = standardized mean difference

^{*} The overall numbers of patients in each group are not necessarily integers owing to inverse probability of treatment weighting.

Supplemental Table 6. Baseline characteristics after overlap weighting.

Baseline characteristics in patients who underwent mechanical aortic valve replacement with an On-X valve or other mechanical valves in Sweden from 2005 to 2018 before and after overlap weighting.

		Unweighted			Overlap weighting		
	Control	On-X	SMD	Control	On-X	SMD	
Number of patients	2021	581		407	407		
Age (years), mean (SD)	54.15 (9.01)	50.97 (10.70)	0.322	51.8 (10.3)	51.8 (10.2)	<0.001	
Female sex	525 (26.0)	106 (18.2)	0.187	83 (20.4)	83 (20.4)	<0.001	
Non-Nordic birth region	207 (10.2)	32 (5.5)	0.176	25 (6.2)	25 (6.2)	<0.001	
Educational level			0.147			<0.001	
<10 years	588 (29.1)	132 (22.7)		97 (23.8)	97 (23.8)		
10-12 years	959 (47.5)	304 (52.3)		210 (51.6)	210 (51.6)		
>12 years	474 (23.5)	145 (25.0)		100 (24.6)	100 (24.6)		
Disposable household income (quartiles)			0.119			<0.001	
Q1 (low)	520 (25.7)	131 (22.5)		95 (23.4)	95 (23.4)		
Q2	506 (25.0)	145 (25.0)		102 (25.1)	102 (25.1)		
Q3	512 (25.3)	138 (23.8)		98 (24.0)	98 (24.0)		
Q4 (high)	483 (23.9)	167 (28.7)		112 (27.5)	112 (27.5)		
Married	1065 (52.7)	261 (44.9)	0.156	190 (46.7)	190 (46.7)	<0.001	
Body mass index (tertiles)			0.053			<0.001	
T1 (low)	623 (30.8)	185 (31.8)		131 (32.1)	131 (32.1)		

T2	778 (38.5)	209 (36.0)		149 (36.7)	149 (36.7)	
T3 (high)	620 (30.7)	187 (32.2)		127 (31.2)	127 (31.2)	
Atrial fibrillation	183 (9.1)	50 (8.6)	0.016	35 (8.5)	35 (8.5)	<0.001
Heart failure	310 (15.3)	72 (12.4)	0.085	52 (12.9)	52.4 (12.9)	<0.001
Left ventricular ejection fraction (%)			0.079			<0.001
>50	1518 (75.1)	435 (74.9)		307 (75.4)	307 (75.4)	
30-50	389 (19.2)	122 (21.0)		83 (20.3)	83 (20.3)	
<30	114 (5.6)	24 (4.1)		17 (4.3)	17 (4.3)	
Chronic obstructive pulmonary disease	136 (6.7)	19 (3.3)	0.159	16 (3.8)	16 (3.8)	<0.001
Diabetes	301 (14.9)	60 (10.3)	0.138	45 (11.0)	45 (11.0)	<0.001
eGFR (ml/min/1,73 m²)			0.153			<0.001
>60	1894 (93.7)	563 (96.9)		392 (96.4)	392 (96.4)	
45-59	85 (4.2)	12 (2.1)		10 (2.4)	10 (2.4)	
30-44	24 (1.2)	4 (0.7)		3 (0.8)	3 (0.8)	
<30	18 (0.9)	2 (0.3)		2 (0.4)	2 (0.4)	
Preoperative dialysis	19 (0.9)	2 (0.3)	0.075	2 (0.4)	2 (0.4)	<0.001
Prior myocardial infarction	193 (9.5)	42 (7.2)	0.084	32 (7.9)	32 (7.9)	<0.001
Prior percutaneous coronary intervention	102 (5.0)	25 (4.3)	0.035	19 (4.6)	19 (4.6)	<0.001
Peripheral vascular disease	208 (10.3)	97 (16.7)	0.188	60 (14.7)	60 (14.7)	<0.001
Hypertension	703 (34.8)	217 (37.3)	0.053	149 (36.6)	149 (36.6)	<0.001
Hyperlipidemia	344 (17.0)	89 (15.3)	0.046	63 (15.6)	63 (15.6)	<0.001
Prior stroke	105 (5.2)	31 (5.3)	0.006	22 (5.4)	22 (5.4)	<0.001

98 (4.8)	30 (5.2)	0.014	22 (5.3)	22 (5.3)	<0.001
69 (3.4)	15 (2.6)	0.049	11 (2.7)	11 (2.7)	<0.001
18 (0.9)	3 (0.5)	0.045	2 (0.6)	2 (0.6)	<0.001
67 (3.3)	15 (2.6)	0.043	11 (2.7)	11 (2.7)	<0.001
92 (4.6)	26 (4.5)	0.004	18 (4.4)	18 (4.4)	<0.001
32 (1.6)	11 (1.9)	0.024	7 (1.7)	7 (1.7)	<0.001
363 (18.0)	79 (13.6)	0.120	59 (14.5)	59 (14.5)	<0.001
		0.390			<0.001
74 (3.7)	32 (5.5)		21 (5.2)	21 (5.2)	
376 (18.6)	117 (20.1)		83 (20.4)	83 (20.4)	
739 (36.6)	259 (44.6)		176 (43.2)	176 (43.2)	
584 (28.9)	157 (27.0)		113 (27.7)	113 (27.7)	
248 (12.3)	16 (2.8)		14 (3.5)	14 (3.5)	
	69 (3.4) 18 (0.9) 67 (3.3) 92 (4.6) 32 (1.6) 363 (18.0) 74 (3.7) 376 (18.6) 739 (36.6) 584 (28.9)	69 (3.4) 15 (2.6) 18 (0.9) 3 (0.5) 67 (3.3) 15 (2.6) 92 (4.6) 26 (4.5) 32 (1.6) 11 (1.9) 363 (18.0) 79 (13.6) 74 (3.7) 32 (5.5) 376 (18.6) 117 (20.1) 739 (36.6) 259 (44.6) 584 (28.9) 157 (27.0)	69 (3.4) 15 (2.6) 0.049 18 (0.9) 3 (0.5) 0.045 67 (3.3) 15 (2.6) 0.043 92 (4.6) 26 (4.5) 0.004 32 (1.6) 11 (1.9) 0.024 363 (18.0) 79 (13.6) 0.120 0.390 74 (3.7) 32 (5.5) 376 (18.6) 117 (20.1) 739 (36.6) 259 (44.6) 584 (28.9) 157 (27.0)	69 (3.4) 15 (2.6) 0.049 11 (2.7) 18 (0.9) 3 (0.5) 0.045 2 (0.6) 67 (3.3) 15 (2.6) 0.043 11 (2.7) 92 (4.6) 26 (4.5) 0.004 18 (4.4) 32 (1.6) 11 (1.9) 0.024 7 (1.7) 363 (18.0) 79 (13.6) 0.120 59 (14.5) 0.390 74 (3.7) 32 (5.5) 21 (5.2) 376 (18.6) 117 (20.1) 83 (20.4) 739 (36.6) 259 (44.6) 176 (43.2) 584 (28.9) 157 (27.0) 113 (27.7)	69 (3.4) 15 (2.6) 0.049 11 (2.7) 11 (2.7) 18 (0.9) 3 (0.5) 0.045 2 (0.6) 2 (0.6) 67 (3.3) 15 (2.6) 0.043 11 (2.7) 11 (2.7) 92 (4.6) 26 (4.5) 0.004 18 (4.4) 18 (4.4) 32 (1.6) 11 (1.9) 0.024 7 (1.7) 7 (1.7) 363 (18.0) 79 (13.6) 0.120 59 (14.5) 59 (14.5) 0.390 74 (3.7) 32 (5.5) 21 (5.2) 21 (5.2) 376 (18.6) 117 (20.1) 83 (20.4) 83 (20.4) 739 (36.6) 259 (44.6) 176 (43.2) 176 (43.2) 584 (28.9) 157 (27.0) 113 (27.7)

Numbers are n (%) unless otherwise specified.

 $eGFR = estimated \ glomerular \ filtration \ rate, \ SD = standard \ deviation, \ SMD = standardized \ mean \ difference$


Supplemental Table 7. Height, weight and body surface area.

	Before matching					
	Overall	Control	On-X	SMD		
Number of patients	2602	2021	581			
Height, cm	175 (9.4)	175 (9.5)	177 (8.8)	0.216		
Weight, kg	86.0 (17.3)	85.5 (17.1)	87.5 (17.8)	0.116		
BSA, m ²	2.04 (0.23)	2.03 (0.23)	2.07 (0.23)	0.154		


Numbers are mean and standard deviation.

BSA = body surface area, SMD = standardized mean difference


Supplemental Figure 1. Proportion of On-X valves by year of surgery.




Supplemental Figure 2. Proportion of On-X valves according to hospital.




Supplemental Figure 3. Histogram of propensity scores before and after matching.




Supplemental Figure 4. Absolute standardized differences before (hollow circles) and after (filled circles) propensity score matching.




Supplemental Figure 5. Proportion of permanent pacemaker implants by year of surgery.



Supplemental Figure 6. Proportion of permanent pacemaker implants according to hospital.




Supplemental Figure 7. Absolute standardized differences before (hollow circles) and after (filled circles) inverse probability of treatment weighting.




Supplemental Figure 8. Absolute standardized differences before (hollow circles) and after (filled circles) overlap weighting.


Note: This method yields exact covariate balance between treated and reference groups by construction.




Supplemental Figure 9. Kaplan-Meier estimated pacemaker implantation rate in the inverse probability of treatment weighted population.



Supplemental Figure 10. Kaplan-Meier estimated pacemaker implantation rate in the overlap weighted population.



Supplemental Figure 11. Crude and adjusted pacemaker implantation rate after On-X valve aortic valve replacement according to alternative approaches for confounding adjustment.



Note: IPTW = inverse probability of treatment weighting, PS = propensity score